Rossari Biotech Limited — Updates, 19-07-2026: Press Release

Rossari Biotech reported Q1 FY27 consolidated revenue up 28% to Rs. 697.2 Cr, EBITDA up 19% to Rs. 80.6 Cr, and PAT up 4% to Rs. 35.1 Cr. The company established a new 5,000 MTPA blending facility in Thailand and completed the sale of its Andheri office, continuing non-core asset monetization.